Erythropoietin alfa
Sponsors
University Eye Hospital, Freiburg, MinYoung Kim, MD, PhD, Bio Sidus SA, Nanogen Pharmaceutical Biotechnology Joint Stock Company, Incepta Pharmaceuticals Ltd
Conditions
-Anemia of Chronic Kidney DiseaseCerebral PalsyHealthyOptic NeuritisPharmacokinetics and Pharmacodynamics in Healthy Volunteers
Phase 1
Phase 3
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
CompletedNCT01962571
Start: 2014-11-25End: 2019-11-26Updated: 2019-12-02
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
CompletedNCT04036253
Start: 2018-02-28End: 2021-08-31Updated: 2025-03-20
PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).
RecruitingNCT07025681
Start: 2025-04-24End: 2025-12-31Target: 56Updated: 2025-06-17